Alba Rodríguez

FDA APPROVES PEMBROLIZUMAB FOR ADVANCED OR METASTATIC ESOPHAGEAL/GASTROESOPHAGEAL JUNCTION CANCER

News /

The United States Food and Drug Administration (FDA) has granted approval for Merck’s anti-programmed death ligand-1 (PD-L1) therapy pembrolizumab (Keytruda) to be used in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinoma. The approval applies specially to treatment of tumors with an epicenter 1 […]

FDA APPROVES PEMBROLIZUMAB FOR ADVANCED OR METASTATIC ESOPHAGEAL/GASTROESOPHAGEAL JUNCTION CANCER Read More »

RISK ASSESSMENT FOR DISTANT METASTASIS IN DIFFERENTIATED THYROID CANCER USING MOLECULAR PROFILING

News /

The authors of this case–control study compared the ThyroSeq genetic profiles of 62 patients with differentiated thyroid cancer with distant metastasis to a propensity-matched cohort without metastatic disease after over 5 years of follow-up. A TERT, TP53, or PIK3CA mutation was found in two-thirds of patients in the cohort with distant metastatic disease. The high-risk

RISK ASSESSMENT FOR DISTANT METASTASIS IN DIFFERENTIATED THYROID CANCER USING MOLECULAR PROFILING Read More »

VALIDATION OF A 22-GENE GENOMIC CLASSIFIER IN PATIENTS WITH RECURRENT PROSTATE CANCER

News /

In this ancillary analysis of the RTOG 9601 study, the researchers validated a 22-gene genomic classifier panel as a predictive biomarker for distant metastases in men with recurrent prostate cancer after radical prostatectomy. The final cohort included 352 men, 89.2% of whom were white. Genomic classifier scores in the final cohort were found to be

VALIDATION OF A 22-GENE GENOMIC CLASSIFIER IN PATIENTS WITH RECURRENT PROSTATE CANCER Read More »

6Q DELETION IN WALDENSTRÖM MACROGLOBULINAEMIA NEGATIVELY AFFECTS TIME TO TRANSFORMATION AND SURVIVAL

News /

Deletion of the long arm of chromosome 6 (del6q) is the most frequent cytogenetic abnormality in Waldenström macroglobulinaemia (WM), occurring in approximately 50% of patients. Its effect on patient outcome has not been completely established. In this study, they used fluorescence in situ hybridisation (FISH) to analyse the prevalence of del6q in selected CD19+ bone

6Q DELETION IN WALDENSTRÖM MACROGLOBULINAEMIA NEGATIVELY AFFECTS TIME TO TRANSFORMATION AND SURVIVAL Read More »

FDA APPROVES FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR HER2-POSITIVE GASTRIC ADENOCARCINOMAS

News /

On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Efficacy was evaluated in a multicenter, open-label, randomized trial (DESTINY-Gastric01, NCT03329690) in patients with HER2-positive locally advanced or metastatic

FDA APPROVES FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR HER2-POSITIVE GASTRIC ADENOCARCINOMAS Read More »

FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG CANCER

News /

In a study published online in The New England Journal of Medicine, Alice T. Shaw and coauthors presented the results of CROWN, a phase III trial evaluating the third-generation tyrosine kinase inhibitor (TKI) lorlatinib in patients with advanced non–small cell lung cancer (NSCLC) harboring an ALK translocation.  ALK translocation and mutations occur in 2% to 7%

FIRST-LINE LORLATINIB OR CRIZOTINIB IN ADVANCED ALK-POSITIVE LUNG CANCER Read More »

MUTANT IDH1 INHIBITOR IVOSIDENIB COMBINED WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

News /

The authors of this phase Ib trial evaluated the oral IDH1 inhibitor ivosidenib in combination with azacitidine in 23 patients with newly diagnosed acute myeloid leukemia ineligible for intensive induction chemotherapy. The overall and complete response rates were 78% and 61%, respectively. The median duration of response and median overall survival were not yet reached

MUTANT IDH1 INHIBITOR IVOSIDENIB COMBINED WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Read More »

OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN HOMOLOGOUS RECOMBINATION–RELATED GENES

News /

The authors of this phase II trial evaluated the PARP inhibitor olaparib in the treatment of 54 patients with metastatic breast cancer (76% ER-positive/HER2-negative) and either germline mutations in non-BRCA1/2 homologous recombination–related DNA repair genes (cohort 1) or somatic mutations in BRCA1/2 or other non-BRCA1/2 homologous recombination–related genes (cohort 2). The objective response rate (ORR)

OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN HOMOLOGOUS RECOMBINATION–RELATED GENES Read More »

FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE‑NEGATIVE BREAST CANCER WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10)

News /

The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10). “Approximately 15-20% of patients with breast cancer are diagnosed with triple-negative breast cancer, which

FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE‑NEGATIVE BREAST CANCER WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10) Read More »

FIVE-YEAR OUTCOMES WITH NIVOLUMAB IN PATIENTS WITH WILD-TYPE BRAF ADVANCED MELANOMA

News /

The authors report the 5-year outcomes of this multicenter, double-blind, phase III study of nivolumab versus dacarbazine for the first-line treatment of 418 patients with unresectable stage III/IV, wild-type BRAF melanoma. Benefits for overall survival, progression-free survival, and objective response rate with nivolumab were confirmed. The 5-year overall survival rate was 39% with nivolumab. Among

FIVE-YEAR OUTCOMES WITH NIVOLUMAB IN PATIENTS WITH WILD-TYPE BRAF ADVANCED MELANOMA Read More »

Descargar más información